Brivaracetam (BRV), a high-affinity synaptic vesicle protein 2A ligand, reported to be 10–30-
fold more potent than levetiracetam (LEV), is highly effective in a wide range of experimental
models of focal and generalized seizures. BRV and LEV similarly bind to synaptic vesicle
protein 2A, while differentiating for other pharmacological effects; in fact, BRV does not
inhibit high voltage Ca2+ channels and AMPA receptors as LEV. Furthermore, BRV
apparently exhibits inhibitory activity on neuronal voltage-gated sodium channels playing a …

Brivaracetam: review of its pharmacology and potential use as adjuncti | DDDT … Register
your specific details and specific drugs of interest and we will match the information you
provide to articles from our extensive database and email PDF copies to you promptly. … For
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms. …